Table 1.
Baseline clinical characteristics of patients in the multicenter vericiguat study versus study versus the VICTORIA trial.
| Characteristics | Overall (N = 285) | VICTORIA trial (N = 5050) | |
| Age, y | 64.8 12.9 | 67.3 12.2 | |
| Female sex | 65 (22.8) | 1208 (23.9) | |
| Hospitalization for HF * | 154/187 (82.4) | 4249 (84.1) | |
| Body mass index, kg/m2 | 24.1 3.6 | 27.8 5.9 | |
| New York Heart Association class | |||
| I | 3 (1.1) | 2/5046 (0.1) | |
| II | 12 (4.2) | 2975/5046 (59.0) | |
| III | 157 (55.1) | 2003/5046 (39.7) | |
| IV | 113 (39.6) | 66/5046 (1.3) | |
| HF duration, y | 3.6 4.4 | 4.8 5.4 | |
| 1.8 (0.6, 5.1) | |||
| Left ventricular ejection fraction | 34.9 10.4 | 28.9 8.3 | |
| Left ventricular ejection fraction 40% | 180/271 (66.4) | 4316 (85.7) | |
| Systolic blood pressure, mm Hg | 124.0 22.1 | 121.4 15.7 | |
| Diastolic blood pressure, mm Hg | 77.9 15.6 | 72.8 11.0 | |
| Heart rate, beats/min | 83.5 19.1 | 73.1 13.0 | |
| Atrial fibrillation or atrial flutter | 53 (18.6) | 2660/5048 (52.7) | |
| Diabetes mellitus | 33 (11.6) | 2369/5048 (46.9) | |
| Hypertension | 97 (34.0) | 3995/5048 (79.1) | |
| Stroke | 29 (10.2) | 578/5048 (11.5) | |
| CAD | 105 (36.8) | 2944/5048 (58.3) | |
| Standard of care treatment | |||
| ACE inhibitor or ARB | 11/284 (3.9) | 3700/5040 (73.4) | |
| Angiotensin receptor–neprilysin inhibitor | 194/284 (68.3) | 731/5040 (14.5) | |
| Beta blocker | 211/284 (74.3) | 4691/5040 (93.1) | |
| MRA | 240/283 (84.8) | 3545/5040 (70.3) | |
| Triple therapy | 149/283 (52.7) | 3009/5040 (59.7) | |
| SGLT2 inhibitor | 195/284 (68.7) | Unknown | |
| Quadruple therapy | 105/283 (37.1) | Unknown | |
| ICD | 32 (11.2) | 1399/5040 (27.8) | |
| Biventricular pacemaker | 24 (8.4) | 739/5040 (14.7) | |
| Laboratory results | |||
| Hemoglobin, g/dL | 13.3 2.2 | 13.4 1.9 | |
| Sodium, mEq/L | 140.5 4.1 | 139.9 3.4 | |
| Potassium, mEq/L | 4.2 0.7 | 4.5 0.5 | |
| Estimated GFR, mL/(min·1.73 m2) | 59.7 (43.7, 88.2) | 58.4 (41.2, 77.1) | |
| Estimated GFR categories | |||
| 30 | 31/241 (12.9) | 506/4959 (10.2) | |
| 30 to 60 | 93/241 (38.6) | 2118/4959 (42.7) | |
| 60 | 117/241 (48.5) | 2335/4959 (47.1) | |
| NT-proBNP, pg/mL | 2915.0 (1074.0, 9020.1) | 2816.0 (1556.0, 5314.0) | |
*In the VICTORIA trial it was hospitalization for HF in the previous 6 months. ACE, angiotensin converting enzyme; ARB, angiotensin receptor blocker; CAD, coronary artery disease; GFR, glomerular filtration rate; ICD, implantable cardioverter-defibrillator; MRA, mineralocorticoid receptor antagonist; NT-proBNP, N-terminal pro-B-type natriuretic peptide; SGLT2, sodium glucose cotransporter 2; y, year; HF, heart failure.